OLEMA PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of the three nominees for Class I director named in the accompanying proxy statement to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Gorjan Hrustanovic, Ph.D.

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gorjan Hrustanovic, Ph.D.”): 44,334,757 for, 1,634,603 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the three nominees for Class I director to hold office until the Company's 2027 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 48 managers: 7,248,325 for, 1,368,261 withheld, 13,179 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 605,000 for.

Description as filed by funds: Election of the three nominees for Class I director named in the accompanying proxy statement to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Ian Clark

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ian Clark”): 33,874,399 for, 12,094,961 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the three nominees for Class I director to hold office until the Company's 2027 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 48 managers: 2,506,262 for, 5,789,863 withheld, 333,640 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 605,000 for.

Description as filed by funds: Election of the three nominees for Class I director named in the accompanying proxy statement to hold office until the Company's 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified: Sandra Horning, M.D.

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Sandra Horning, M.D.”): 40,102,098 for, 5,867,262 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1—Election of Directors Final Voting Results The Company's stockholders elected each of the three nominees for Class I director to hold office until the Company's 2027 annual meeting of stockholders and until their respective successors have been duly elected and qualified.”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 48 managers: 5,779,638 for, 2,527,281 withheld, 322,846 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 605,000 for.

Description as filed by funds: Approval, on an advisory basis, of the compensation of the Company's named executive officers.

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory Vote on Executive Compensation Final Voting Results”): 45,174,223 for, 787,068 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation awarded to the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of OLEMA PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (2 managers, 250,394 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 48 managers: 8,586,597 for, 43,168 against. Showing the 25 largest; see all in the interactive database.

No total is shown for the institutional-manager reports: their sum exceeds the total votes cast at the meeting. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.

OLEMA PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”): 48,366,695 for, 19,160 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm Final Voting Results”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 48 managers: 8,629,765 for. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 1 managers: 605,000 for.